Salvage by timed sequential chemotherapy in primary resistant acute myeloid leukemia: Analysis of prognostic factors

Annals of Hematology

Volumn 82, Issue 11, 2003, Pages 684-690

  Revesz, D ^a   Chelghoum, Y ^a   Le, Q H ^a,b   Elhamri, M ^a   Michallet, M ^a   Thomas, Xavier ^a  

^a EDOUARD HERRIOT HOSPITAL   (France)

^b CENTRE HOSPITALIER LYON SUD   (France)

Author keywords

Acute myeloid leukemia; Prognosis; Resistance; Salvage chemotherapy

Indexed keywords

AMSACRINE; ANTHRACYCLINE; ANTINEOPLASTIC AGENT; CARBOPLATIN; CYTARABINE; DAUNORUBICIN; DOXORUBICIN; ETOPOSIDE; LOMUSTINE; MERCAPTOPURINE; MITOXANTRONE; RECOMBINANT GRANULOCYTE COLONY STIMULATING FACTOR;

ACUTE GRANULOCYTIC LEUKEMIA; ADOLESCENT; ADULT; AGED; APLASIA; ARTICLE; BLAST CELL; BLEEDING; CANCER ADJUVANT THERAPY; CANCER RECURRENCE; CARDIOTOXICITY; CAUSE OF DEATH; CHROMOSOME ABERRATION; CLINICAL TRIAL; CONFIDENCE INTERVAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DOSE RESPONSE; FEMALE; FOLLOW UP; HEMATOLOGIC DISEASE; HLA MATCHING; HUMAN; INFECTION; KARYOTYPING; LEUKEMIA REMISSION; LEUKOCYTE COUNT; LIVER TOXICITY; MAINTENANCE THERAPY; MAJOR CLINICAL STUDY; MALE; MEDICAL DECISION MAKING; MUCOSA INFLAMMATION; MULTIVARIATE ANALYSIS; NAUSEA AND VOMITING; PRIORITY JOURNAL; PROGNOSIS; RISK ASSESSMENT; SALVAGE THERAPY; SIBLING; SKIN TOXICITY; STEM CELL TRANSPLANTATION; SURVIVAL TIME; TREATMENT FAILURE; TREATMENT OUTCOME; TREATMENT PLANNING;

ADOLESCENT; ADULT; AGED; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CYTARABINE; DRUG ADMINISTRATION SCHEDULE; ETOPOSIDE; FEMALE; HUMANS; LEUKEMIA, MYELOCYTIC, ACUTE; LEUKOCYTE COUNT; MALE; MIDDLE AGED; MITOXANTRONE; NEOPLASM RECURRENCE, LOCAL; PROGNOSIS; REMISSION INDUCTION; SALVAGE THERAPY; SURVIVAL RATE;

EID: 0345376017     PISSN: 09395555     EISSN: None     Source Type: Journal    
DOI: 10.1007/s00277-003-0730-1     Document Type: Article

References (30)

1. Amadori S, Arcese W, Isacchi G, Meloni G, Petti MC, Monarca B, Testi AM, Mandelli F (1991) Mitoxantrone, etoposide and intermediate dose cytarabine: an effective and tolerable regimen for the treatment of refractory acute myeloid leukemia. J Clin Oncol 9:1210-1214
2. Archimbaud E, Leblond V, Michallet M, Cordonnier C, Fenaux P, Travade P, Dreyfus F, Jaubert J, Devaux Y, Fiere D (1991) Intensive sequential chemotherapy with mitoxantrone and continuous infusion etoposide and cytarabine for resistant or relapsing acute myelogenous leukemia. Blood 77:1894-1900
3. Archimbaud E, Anglaret B, Thomas X, Devaux Y, Ffrench M, Sebban C, Troncy J, Fiere D (1992) Continuous-infusion daunorubicin and carboplatin for high-risk acute myeloid leukemia in the elderly. Leukemia 6:776-779
4. Archimbaud E, Thomas X, Michallet M, Jaubert J, Troncy J, Guyotat D, Fiere D (1994) Prospective genetically randomized comparison between intensive postinduction chemotherapy and bone marrow transplantation in adults with newly diagnosed acute myeloid leukemia. J Clin Oncol 12:262-267
5. Archimbaud E, Thomas X, Leblond V, Michallet M, Fenaux P, Cordonnier C, Dreyfus F, Troussard X, Jaubert J, Travade Ph, Troncy J, Assouline D, Fière D (1995) Timed sequential chemotherapy for previously treated patients with acute myeloid leukemia: long-term follow-up of the etoposide, mitoxantrone, and cytarabine-86 trial. J Clin Oncol 13:11-18
6. Bennett JM, Catovsky D, Daniel MT, Flandrin G, Galton DAG, Gralnick HR, Sultan C (1985) Proposed revised criteria for the classification of acute myeloid leukemia: a report of the French-American-British Cooperative Group. Ann Intern Med 103:626-629
7. Brown RA, Herzig RH, Wolff SN, Frei-Lahr D, Pineiro L, Bolwell BJ, Lowder JN, Harden EA, Hande KR, Herzig GP (1990) High dose etoposide and cyclophosphamide without bone marrow transplantation for resistant hematologic malignancy. Blood 76:473-479
8. Burke PJ, Vaughan WP, Karp JE (1980) A rationale for sequential high-dose chemotherapy of leukemia timed to coincide with induced tumor proliferation. Blood 55:960-968
9. Castaigne S, Archimbaud E, Bordessoule D, Fenaux P, Tilly H, de Revel T, Simon M, Janvier M, Renoux M, Grosbois M, Dupriez B, Zini JM, Tertian G, Legros M, Chastang C, for the AML Study Group (1996) Preliminary results of LAM90 trial on adult acute myelogenous leukemia: comparison of standard induction chemotherapy versus double or sequential induction chemotherapy. Br J Haematol 93 [Suppl 2]:133
10. Clift R (1987) The treatment of acute nonlymphoblastic leukemia by allogeneic marrow transplantation. Bone Marrow Transplant 2:243-258
11. Chopra R, Goldstone AH, McMillan AK (1991) Successful treatment of acute myeloid leukemia beyond first remission with autologous bone marrow transplantation using busulfan/ cyclophosphamide and unpurged marrow: the British Autograft Group experience. J Clin Oncol 9:1840-1847
12. Davis CL, Rohatiner AZS, Lim J, Whelan JS, Oza AM, Amess J, Love S, Stead E, Lister TA (1993) The management of recurrent acute myelogenous leukemia at a single center over a fifteen-year period. Br J Haematol 83:404-411
13. De Witte T, Suciu S, Sellestag D, Labar B, Roozendaal K, Zittoun R, Ribeiro M, Kurstjens R, Hayat M, Dardenne M, Solbu G, Muus P (1996) Salvage treatment for primary resistant acute myelogenous leukemia consisting of intermediate-dose cytosine arabinoside and interspaced continuous infusions of idarubicin: a phase-II study (no. 06901) of the EORTC Leukemia Cooperative Group. Ann Hematol 72:119-124
14. De Witte T, Suciu S, Zittoun R, Resegotti L, Liso V, Willemze R, Belhabri A, Amadori S, Giustolisi R, Labar B, Fioritoni G, Rossi-Ferrini G, Leone G, Jehn U, Keating S, Fazi P, Rodts P, Solbu G, Mandelli F (2000) The type of anthracycline administered during remission induction and consolidation therapy of AML has an impact on feasibility of subsequent autologous or allogeneic transplantation and induced marrow toxicity: preliminary results of the EORTC/GIMEMA AML-10 randomized trial (abstract 2167). Blood 96
15. Ellison RR, Holland JF, Weil M, Jacquillat C, Boiron M, Bernard J, Sewitsky A, Rosner F, Gussoff B, Silver RT, Karanas A, Cuttner J, Spurr CL, Hayes DM, Bloom J, Leone LA, Haurani F, Kyle R, Hutchison JL, Forcier RJ, Moon JH (1968) Arabinosyl cytosine: a useful agent in the treatment of acute leukemia in adults. Blood 32:507-523
16. Gorin N, Labopin M, Meloni G, Korbling M, Carella A, Hervé P, Burnett A, Rizzoli V, Alessandrino EP, Bjorkstrand B, et al. (1991) Autologous bone marrow transplantation for acute myeloblastic leukemia in Europe: further evidence of the role of marrow purging by mafosfamide. Leukemia 5:896-904
17. Ho A, Lipp T, Ehninger G, Illiger HJ, Meyer P, Freund M, Hunstein W (1988) Combination of mitoxantrone and etoposide in refractory acute myelogenous leukemia: an active and well tolerated regimen. J Clin Oncol 6:213-217
18. Kantarjian HM, Beran M, Ellis A, Zwelling L, O'Brien S, Cazenave L, Koller C, Rios MB, Plunkett W, Keating MJ, et al. (1993) Phase I study of topotecan, a new topoisomerase I inhibitor in patients with refractory or relapsed acute leukemia. Blood 81:1146-1151
19. Karp JE, Donehower RC, Enterline JP, Dole GB, Fox MG, Burke PJ (1989) In vivo cell growth and pharmacologic determinants of clinical response in acute myelogenous leukemia. Blood 73:24-30
20. Löwenberg B, Suciu S, Archimbaud E, Haak H, Stryckmans P, de Cataldo R, Dekker AW, Berneman ZN, Thyss A, van der Lelie J, Sonneveld P, Visani G, Fillet G, Hayat M, Hagemeijer A, Solbu G, Zittoun R (1998) Mitoxantrone versus daunorubicin in induction-consolidation chemotherapy, the value of low-dose cytarabine for maintenance of remission, and an assessment of prognostic factors in acute myeloid leukemia in the elderly: final report of the Leukemia Cooperative Group of the European Organization for the Research and Treatment of Cancer and the Dutch-Belgian Hemato-Oncology Cooperative Hovon Group. Randomized phase III study AML-9. J Clin Oncol 16:872-881
21. Martinez J, Martin G, Sanz G, Sempere A, Jarque I, de la Rubia J, Sanz MA (1991) A phase II clinical trial of carboplatin infusion in high risk nonlymphoblastic leukemia. J Clin Oncol 9:39-43
22. Meloni G, De Fabritiis P, Petti MC, Mandelli F (1990) BAVC regimen and autologous bone marrow transplantation in patients with acute myelogenous leukemia in second remission. Blood 75:2282-2285
23. Preisler HD (1978) Failure of remission induction in acute myelocytic leukemia. Med Ped Oncol 4:275-276
24. Reiffers J, Stoppa AM, Attal M, Michallet M, Marit G, Blaise D, Huguet F, Corront B, Cony-Makhoul P, Gastaut JA, Laurent G, Molina L, Broustet A, Maraninchi D, Pris J, Hollard D, Faberes C (1996) Allogeneic vs autologous stem cell transplantation vs chemotherapy in patients with acute myeloid leukemia in first remission: the BGMT 87 study. Leukemia 10:1874-1882
25. Santana VM, Mirro JJr, Kearns C, Schell MJ, Crom W, Blakley RL (1992) 2-chlorodeoxyadenosine produces a high rate of complete hematologic remission in relapsed acute myeloid leukemia. J Clin Oncol 10:364-370
26. Stanisic S, Kalaycio M (2002) Treatment of refractory and relapsed acute myelogenous leukemia. Expert Rev Anticancer Ther 2:287-295
27. Tavernier E, Le QH, Elhamri M, Thomas X (2003) Salvage therapy in refractory acute myeloid leukemia: prediction of outcome based on analysis of prognostic factors. Leuk Res 27:205-214
28. Thomas X, Fenaux P, Dombret H, Delair S, Dreyfus F, Tilly H, Vekhoff A, Cony-Makhoul P, Leblond V, Troussard X, Cordonnier C, de Revel T, Simon M, Nicolini F, Stoppa AM, Janvier M, Bordessoule D, Rousselot P, Ffrench M, Marie JP, Archimbaud E (1999) Granulocyte-macrophage colony-stimulating factor (GM-CSF) to increase efficacy of intensive sequential chemotherapy with etoposide, mitoxantrone and cytarabine (EMA) in previously treated acute myeloid leukemia: a multicenter randomized placebo-controlled trial (EMA91 trial). Leukemia 13:1214-1220
29. Vernant JP, Leblond V, Dreyfus F, Colombat P, Pesca A, Troussard X, Allard O, Cordonnier C, Kuentz M, Karianakis G: Bierling P, Rochant H (1986) Results of CHA in adults with acute myeloid leukemia (abstract). IVth International Symposium on Therapy of Acute Leukemias, Rome
30. World Health Organization (1979) WHO handbook for reporting results of cancer treatment, WHO offset publication 48. WHO, Geneva